Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability. (PubMed, Bone) - Sep 27, 2026 - "Specifically, by inhibiting HDAC6, RICO promoted proteasomal degradation of p65 by increasing its acetylation and ubiquitination, thereby reducing p65 protein abundance in both cytoplasmic and nuclear fractions and suppressing canonical NF-κB signaling. Collectively, these findings identify RICO-as a phase II clinical stage investigational compound with repurposing potential as a promising anti-resorptive candidate for the treatment of osteoporosis and uncover a novel mechanism whereby HDAC6 governs p65 protein stability to inhibit osteoclastogenesis."
Journal • Osteoporosis • Rheumatology • Targeted Protein Degradation
|
|
Chen Shuomin; Chen Yang; Deng Qingzhou; Hao Fangdan; Huang Shengbin; Jiang Haofu; Li Bin; Li Wangzhi; Ma Xinyi; Mao Yixin; Ping Yifan; Tu Junhao; Wang Jialiang; Wang Yongkai; Wu Suxin; Yi Mengjia; Zhao Shufan
|